2018 Winship Melanoma Conference - priME Oncology
prIME Downloadable Slides
prIME Downloadable Slides

2018 Winship Melanoma Conference

Winship Cancer Institute

Not a member of My prIME? Join now for instant access.

Downloadable slides from the 2018 Winship Melanoma Conference

Downloadable Slides

Downloadable Slides

Release Date

Release Date

Mar 23, 2018

Expiration Date

Mar 23, 2019

Featured Expert

  • Sancy Leachman, MD, PhD, Knight Cancer Institute, Portland, Oregon, United States

Featured Topic

War on melanoma:  Taking it to the streets with mole mapping cancer screening

Featured Expert

  • Mohammad K. Khan, MD, PhD, DABR, Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

Featured Topic

Radiation for nonmelanoma skin cancers in the dermatologist’s office: A radiation oncologist’s (generally positive) perspective

Featured Expert

  • John T. Seykora, MD, PhD, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States

Featured Topic

Molecular characterization of stage I – III melanoma: How close are we to accurate prognostication and prediction?

Featured Expert

  • Rajini Murthy, MD, Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

Featured Topic

More skin in the game: Multidisciplinary management of cutaneous adverse events of targeted and immunotherapeutic agents

Featured Expert

  • Jeffrey Gershenwald, MD, The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States

Featured Topic

Update on new AJCC Staging System for melanoma: What are the changes and why?

Featured Expert

  • Jeffrey Gershenwald, MD, The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States

Featured Topic

Approach to the nodal basin: Should we just leave it alone?

Featured Expert

  • David Lawson, MD, Emory University, Winship Cancer Center, Atlanta, Georgia, United States

Featured Topic

Adjuvant therapy of melanoma: Beyond ipilimumab?

Featured Expert

  • Ragini Kudchadkar, MD, Emory University, Winship Cancer Center, Atlanta, Georgia, United States

Featured Topic

Update on Merkel cell carcinoma and other nonmelanoma skin cancers: The times they are a-changing

Featured Expert

  • Ragini Kudchadkar, MD, Emory University, Winship Cancer Center, Atlanta, Georgia, United States

Featured Topic

Update on uveal melanoma: At least a glimmer of light

Featured Expert

  • Michael Lowe, MD, Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

Featured Topic

Multidisciplinary approach to metastatic melanoma: Systemic therapy before surgery or instead of surgery?

Featured Expert

  • Hussein Tawbi, MD, PhD, University of Pittsburgh , Pittsburgh, Pennsylvania, United States

Featured Topic

Management of melanoma brain metastases: Much more to think about

Featured Expert

  • David Lawson, MD, Emory University, Winship Cancer Center, Atlanta, Georgia, United States

Featured Topic

Molecular testing of metastatic melanoma: Which test(s), when, how to interpret

Featured Expert

  • Ragini Kudchadkar, MD, Emory University, Winship Cancer Center, Atlanta, Georgia, United States

Featured Topic

Optimization of the use of immunotherapy and targeted agents by aggressive management of noncutaneous adverse events

Featured Expert

  • David Lawson, MD, Emory University, Winship Cancer Center, Atlanta, Georgia, United States

Featured Topic

Systemic therapy for metastatic melanoma: Decisions and sequencing

After successful completion of this educational activity, participants should be able to:

  • Describe best practices for diagnosis and risk assessment for melanoma, Merkel cell carcinoma, or uveal melanoma, including the appropriate use of molecular testing
  • Identify patients who should receive radiotherapy, either alone or in combination with other therapeutic modalities
  • Assess best practices for surgical management of metastatic melanoma
  • Evaluate the risks and benefits of novel treatment strategies for patients with melanoma, Merkel cell carcinoma, or uveal melanoma, as well as the practical utility of these approaches based on recent clinical data
  • Identify strategies to manage adverse events associated with novel systemic treatment options

This educational activity is specifically designed to meet the needs of dermatologists, medical, surgical, radiation oncologists, and other healthcare professionals involved in the treatment of patients with melanoma and other skin malignancies.

This educational activity is supported by grants from Bristol-Myers Squibb; Merck and Co, Inc.; and Novartis Oncology.

Enduring Material From a Certified Activity

This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.

Provider

This activity is jointly provided by prIME Oncology and Winship Cancer Institute of Emory University.

Disclosure Information

Disclosure of Relevant Financial Relationships

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Gershenwald has disclosed membership on the advisory board of Merck. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Khan has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Kudchadkar has disclosed that she has received consulting fees from Array and Bristol-Myers Squibb. She has also received research funding from Merck. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Lawson has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Leachman has disclosed that she is a medical director at Skin Cancer Free, Inc. She also disclosed membership on the boards of Castle Biosciences and Myriad Genetics Laboratory. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Lowe has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Murthy has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Seykora has disclosed that he has received honoraria for a promotional speaker’s bureau from Myriad Genetics and independent contracting for Piqur Therapeutics and Rohto Pharmaceutical. He also disclosed intellectual property rights for an application of topical kinase inhibitors to treat skin cancer.  He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Tawbi has disclosed that he has received consulting fees from Bristol-Myers Squibb, Genentech, Merck, and Novartis.  He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Briana Betz, PhD (scientific content reviewer/planner) – no relevant financial relationships
  • Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.